User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.

Primary tabs

Chiesa, Carlo Sjogreen Gleisner, Katarina Flux, Glenn Gear, Jonathan Walrand, Stephan [UCL] Konijnenberg, Mark W
Document type Article de périodique (Journal article) – Éditorial
Access type Accès restreint
Publication date 2017
Language Anglais
Journal information "European Journal of Nuclear Medicine and Molecular Imaging" - Vol. 44, no.11, p. 1783-1786 (2017)
Peer reviewed yes
Publisher Springer Verlag ((Germany) Berlin)
issn 1619-7070
e-issn 1619-7089
Publication status Publié
Affiliations UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - (SLuc) Service de radiothérapie oncologique
Links
  1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.
  2. LEEPER ROBERT D., The Effect of131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma, 10.1210/jcem-36-6-1143
  3. Lee Jong Jin, Chung June-Key, Kim Sung Eun, Kang Won Jun, Park Do Joon, Lee Dong Soo, Cho Bo Youn, Lee Myung Chul, Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma, 10.1007/s12149-007-0179-8
  4. Klubo-Gwiezdzinska Joanna, Van Nostrand Douglas, Atkins Frank, Burman Kenneth, Jonklaas Jacqueline, Mete Mihriye, Wartofsky Leonard, Efficacy of DosimetricVersusEmpiric Prescribed Activity of131I for Therapy of Differentiated Thyroid Cancer, 10.1210/jc.2011-0494
  5. Verburg Frederik A., Hänscheid Heribert, Biko Johannes, Hategan Maria C., Lassmann Michael, Kreissl Michael C., Reiners Christoph, Luster Markus, Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience, 10.1007/s00259-009-1303-x
  6. Bianchi L, Baroli A, Lomuscio G, Pedrazzini L, Pepe A, Pozzi L, et al. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio hospital (Italy). Q J Nucl Med Mol Imaging. 2012;56:515–21.
  7. Dorn R, Kopp J, Vogt H, Heidenreich P, Carrol RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451–6.
  8. Hartung-Knemeyer Verena, Nagarajah James, Jentzen Walter, Ruhlmann Marcus, Freudenberg Lutz S., Stahl Alexander R., Bockisch Andreas, Rosenbaum-Krumme Sandra J., Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies, 10.1007/s12149-012-0632-1
  9. Verburg Frederik A., , Luster Markus, Giovanella Luca, Lassmann Michael, Chiesa Carlo, Chouin Nicolas, Flux Glenn, The “reset button” revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients, 10.1007/s00259-017-3649-9
  10. Fielding S. L., Flower M. A., Ackery D., Kemshead J. T., Lashford L. S., Lewis I., Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study, 10.1007/bf02285457
  11. Buckley Susan E., Saran Frank H., Gaze Mark N., Chittenden Sarah, Partridge Mike, Lancaster Donna, Pearson Andrew, Flux Glenn D., Dosimetry for Fractionated 131I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results, 10.1089/cbr.2007.301
  12. Chiesa C., Mira M., Maccauro M., Spreafico C., Romito R., Morosi C., Camerini T., Carrara M., Pellizzari S., Negri A., Aliberti G., Sposito C., Bhoori S., Facciorusso A., Civelli E., Lanocita R., Padovano B., Migliorisi M., De Nile M. C., Seregni E., Marchianò A., Crippa F., Mazzaferro V., Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology, 10.1007/s00259-015-3068-8
  13. Gnesin S., Canetti L., Adib S., Cherbuin N., Silva Monteiro M., Bize P., Denys A., Prior J. O., Baechler S., Boubaker A., Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison, 10.2967/jnumed.116.173104
  14. Strosberg Jonathan, El-Haddad Ghassan, Wolin Edward, Hendifar Andrew, Yao James, Chasen Beth, Mittra Erik, Kunz Pamela L., Kulke Matthew H., Jacene Heather, Bushnell David, O’Dorisio Thomas M., Baum Richard P., Kulkarni Harshad R., Caplin Martyn, Lebtahi Rachida, Hobday Timothy, Delpassand Ebrahim, Van Cutsem Eric, Benson Al, Srirajaskanthan Rajaventhan, Pavel Marianne, Mora Jaime, Berlin Jordan, Grande Enrique, Reed Nicholas, Seregni Ettore, Öberg Kjell, Lopera Sierra Maribel, Santoro Paola, Thevenet Thomas, Erion Jack L., Ruszniewski Philippe, Kwekkeboom Dik, Krenning Eric, Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, 10.1056/nejmoa1607427
  15. Sundlöv Anna, Sjögreen-Gleisner Katarina, Svensson Johanna, Ljungberg Michael, Olsson Tomas, Bernhardt Peter, Tennvall Jan, Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry, 10.1007/s00259-017-3678-4
  16. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46:99S–106S.
  17. Kletting P., Kull T., Maass C., Malik N., Luster M., Beer A. J., Glatting G., Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy, 10.2967/jnumed.115.164699
  18. Bergsma Hendrik, Konijnenberg Mark W., van der Zwan Wouter A., Kam Boen L. R., Teunissen Jaap J. M., Kooij Peter P., Mauff Katya A. L., Krenning Eric P., Kwekkeboom Dik J., Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate, 10.1007/s00259-016-3382-9
  19. Chiesa Carlo, The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y-microspheres, 10.1016/j.ejmp.2016.07.264
  20. Cremonesi Marta, Chiesa Carlo, Strigari Lidia, Ferrari Mahila, Botta Francesca, Guerriero Francesco, De Cicco Concetta, Bonomo Guido, Orsi Franco, Bodei Lisa, Di Dia Amalia, Grana Chiara Maria, Orecchia Roberto, Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective, 10.3389/fonc.2014.00210
  21. Mazzaferro Vincenzo, Sposito Carlo, Bhoori Sherrie, Romito Raffaele, Chiesa Carlo, Morosi Carlo, Maccauro Marco, Marchianò Alfonso, Bongini Marco, Lanocita Rodolfo, Civelli Enrico, Bombardieri Emilio, Camerini Tiziana, Spreafico Carlo, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study, 10.1002/hep.26014
  22. Sjogreen Gleisner K. Current status and preparedness to comply to the Directive (report on European survey). Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S22 OP052.
  23. Garin E., Boucher E., Rolland Y., 99mTc-MAA-Based Dosimetry for Liver Cancer Treated Using 90Y-Loaded Microspheres: Known Proof of Effectiveness, 10.2967/jnumed.114.137422
  24. Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89:20150943.
  25. Willowson Kathy P., , Tapner Michael, Bailey Dale L., A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : The QUEST Phantom Study, 10.1007/s00259-015-3059-9
  26. Smits Maarten LJ, Nijsen Johannes FW, van den Bosch Maurice AAJ, Lam Marnix GEH, Vente Maarten AD, Mali Willem PTM, van het Schip Alfred D, Zonnenberg Bernard A, Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study, 10.1016/s1470-2045(12)70334-0
Bibliographic reference Chiesa, Carlo ; Sjogreen Gleisner, Katarina ; Flux, Glenn ; Gear, Jonathan ; Walrand, Stephan ; et. al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, no.11, p. 1783-1786 (2017)
Permanent URL http://hdl.handle.net/2078.1/201732